Patients unaware of risks and purpose of research even after informed consent

December 07, 2006

As many as two-thirds of critically ill patients who consented to take part in a clinical trial do not remember the purpose and risks of the research shortly after. A small study published today in the journal Critical Care, reveals that most Intensive Care Unit (ICU) patients who gave their informed consent to take part in a clinical trial remembered having participated in the trial ten days later. But two-thirds of the patients did not remember the purpose and risks of the trial, although they had been given information about them before the trial started.

Catherine Chenaud and colleagues from the University Hospital of Geneva, Switzerland, studied 44 ICU patients who had been selected for a clinical trial on inflammatory responses. The patients were given a 20-minute presentation about the study, its purpose and its risks and were given a leaflet to read, before agreeing to participate in the trial. They were then interviewed ten days later.

Chenaud et al.' s results show that 35/44 patients remembered having taken part in the trial, but that only 20/44 patients remembered the purpose of the study and only 21/44 patients remembered the study risks. Furthermore, only 14/44 patients remembered both the purpose of the trial and its associated risks. The 14 patients who remembered all aspects of the trial did not differ from other patients, except that they had read the leaflet or had asked at least one question during the presentation, before signing the consent form.

The authors conclude that obtaining informed consent from patients should be a process which is revisited many times, rather than one event at the start of the trial, and that patients should be given information repeatedly during the course of a trial.
-end-
Article:
Informed consent for research obtained during the ICU stay
Catherine Chenaud MD, Paolo Merlani MD, Samuel Luyasu MD and Bara Ricou
Critical Care 2006 (in press)

BioMed Central

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.